FDA approves Braftovi + Mektovi combination in a melanoma indication

Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”

Last week’s issue of The Cancer Letter featured great news and terrible news.

December 10, 2025

Anthony Letai pledges to ensure stability for extramural and intramural cancer science

Stepping into the NCI director’s job at the end of a nerve-racking year, Anthony Letai wants you to know that the federal government is not going out of the business of cancer research.

December 05, 2025

Vol.51 No.44

By Paul Goldberg

NCI

In first NCAB director’s report, Anthony Letai focuses on centralized grant review, budget outlook

Anthony G. Letai’s initiation as the 18th director of the National Cancer Institute wasn’t exactly smooth.

Pazdur leaves FDA after 25-year career that shaped the agency’s oncology regulations
BIO calls for the end of “constant turmoil,” urges the administration to “right the ship”

After three weeks of brutal combat, Richard Pazdur decided that he has had enough.

Mail-out colorectal cancer screening programs extend, rather than replace, clinical care

As a gastroenterologist, I’ve had the sobering experience of delivering a colorectal cancer diagnosis for far too many patients and family members. Some meant to get screened but never found the time. Others thought it didn’t apply to them or assumed it would be too inconvenient.

December 05, 2025

Vol.51 No.44

By Paul J. Limburg

Fixing site reads without burning out the readers
Yunu modernizes clinical trial imaging assessment workflows

Imaging assessments are a requirement for most oncology trial endpoints. Yet, many cancer centers are still trying to support research trials with clinical care tools and ad hoc processes that are not fit-for-purpose and don’t meet the needs of sponsors or trial staff.

December 05, 2025

Vol.51 No.44

By Jeff Sorenson

FDA approves Braftovi + Mektovi combination in a melanoma indication

YOU MAY BE INTERESTED IN

Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”

Anthony Letai pledges to ensure stability for extramural and intramural cancer science

In first NCAB director’s report, Anthony Letai focuses on centralized grant review, budget outlook

Pazdur leaves FDA after 25-year career that shaped the agency’s oncology regulations
BIO calls for the end of “constant turmoil,” urges the administration to “right the ship”

Mail-out colorectal cancer screening programs extend, rather than replace, clinical care

Fixing site reads without burning out the readers
Yunu modernizes clinical trial imaging assessment workflows

Renew today!

Subscriber content

Never miss an issue!

Login

FDA approves Braftovi + Mektovi combination in a melanoma indication

YOU MAY BE INTERESTED IN

Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”

Anthony Letai pledges to ensure stability for extramural and intramural cancer science

In first NCAB director’s report, Anthony Letai focuses on centralized grant review, budget outlook

Pazdur leaves FDA after 25-year career that shaped the agency’s oncology regulationsBIO calls for the end of “constant turmoil,” urges the administration to “right the ship”

Mail-out colorectal cancer screening programs extend, rather than replace, clinical care

Fixing site reads without burning out the readersYunu modernizes clinical trial imaging assessment workflows

Never miss an issue!

Login

Pazdur leaves FDA after 25-year career that shaped the agency’s oncology regulations
BIO calls for the end of “constant turmoil,” urges the administration to “right the ship”

Fixing site reads without burning out the readers
Yunu modernizes clinical trial imaging assessment workflows